8-K: Walgreens Boots Alliance Reports Mixed Q2 Results, Faces Significant Impairment Charge

Walgreens Boots Alliance reported a net loss due to a substantial non-cash impairment charge related to VillageMD, while adjusted earnings per share saw a modest increase.

Summary

• Walgreens Boots Alliance (WBA) announced its financial results for the second quarter of fiscal year 2024, which ended on February 29, 2024.
• The company experienced a net loss of $5.9 billion, or $6.85 per share, compared to a net profit of $703 million, or $0.81 per share, in the same quarter last year.
• This loss was primarily due to a $5.8 billion after-tax non-cash impairment charge related to VillageMD goodwill and a $455 million non-cash impairment charge related to certain long-lived assets in the U.S. Retail Pharmacy segment.
• However, adjusted earnings per share (EPS) increased by 3.4% to $1.20, or 2.8% on a constant currency basis.
• Second quarter sales increased by 6.3% year-over-year to $37.1 billion, or 5.7% on a constant currency basis.
• The company is narrowing its fiscal year 2024 adjusted EPS guidance to $3.20 to $3.35, reflecting a challenging retail environment in the U.S., the early wind-down of a sale-leaseback program, and lower earnings due to Cencora share sales.
• WBA is maintaining its U.S. Healthcare adjusted EBITDA to be breakeven at the midpoint of the guidance range of ($50) million to $50 million.
• The U.S. Healthcare segment achieved its first quarter of positive adjusted EBITDA at $17 million, a $127 million improvement year-over-year.
• Free cash flow was negative $610 million, a $1.3 billion decrease compared with the year-ago quarter.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant net loss and impairment charge, despite some positive aspects like adjusted EPS growth and U.S. Healthcare EBITDA. The challenges in the retail environment and cash flow are concerning.

Positives

• Adjusted earnings per share increased by 3.4% to $1.20, or 2.8% on a constant currency basis.
• Second quarter sales increased by 6.3% year-over-year to $37.1 billion, or 5.7% on a constant currency basis.
• The U.S. Healthcare segment achieved its first quarter of positive adjusted EBITDA at $17 million.
• The company is maintaining its U.S. Healthcare adjusted EBITDA to be breakeven at the midpoint of the guidance range of ($50) million to $50 million.
• WBA is aiming for $1 billion in cost savings this year.
• Boots.com sales grew 16.8%, representing over 17% of Boots total retail sales.

Negatives

• WBA reported a net loss of $5.9 billion, or $6.85 per share, due to a $5.8 billion non-cash impairment charge related to VillageMD goodwill.
• Operating loss was $13.2 billion compared to an operating income of $197 million in the year-ago quarter.
• Free cash flow was negative $610 million, a $1.3 billion decrease compared with the year-ago quarter.
• Adjusted operating income decreased 26.5% on a constant currency basis.
• Retail sales decreased 4.5% and comparable retail sales decreased 4.3% in the U.S. Retail Pharmacy segment.
• Adjusted operating income in the International segment decreased 30.3% to $245 million, or 32.4% on a constant currency basis.

Risks

• The company faces a challenging retail environment in the U.S.
• The early wind-down of the sale-leaseback program is impacting earnings.
• Lower earnings are expected due to Cencora share sales.
• The company is experiencing higher shrink levels in the U.S. Retail Pharmacy segment.
• The company is facing adverse impacts from a weaker respiratory season and adverse January weather.
• The company is facing legal matters that have negatively impacted cash flow.

Future Outlook

WBA is narrowing its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35 and maintaining U.S. Healthcare adjusted EBITDA to be breakeven at the midpoint of the guidance range of ($50) million to $50 million. The company is also strategically reviewing its portfolio over the next three months.

Management Comments

• CEO Tim Wentworth stated they were encouraged by the first quarter of U.S. Healthcare positive adjusted EBITDA and continued topline growth.
• He also mentioned the company is taking actions to focus on customer engagement and value in a challenging retail environment.
• Management remains confident in achieving $1 billion in cost savings this year.
• The company is strategically reviewing its portfolio over the next three months to ensure it drives growth and delivers value.

Industry Context

The results reflect a challenging retail environment, which is impacting many companies in the sector. The focus on cost savings and strategic portfolio review suggests WBA is adapting to these challenges. The growth in the U.S. Healthcare segment is a positive sign, indicating a potential shift in focus for the company.

Comparison to Industry Standards

• WBA's adjusted EPS growth of 3.4% is modest compared to some competitors in the healthcare and retail space, but the significant impairment charge skews the overall picture.
• CVS Health, for example, has shown stronger growth in certain segments, but also faces challenges in the retail sector.
• The positive adjusted EBITDA in the U.S. Healthcare segment is a notable achievement, as many healthcare providers are struggling with profitability.
• The decline in retail sales is consistent with trends seen in other brick-and-mortar retailers, highlighting the ongoing shift to e-commerce.
• The company's focus on cost savings is a common strategy among retailers facing economic headwinds, similar to actions taken by companies like Rite Aid and Walmart.

Stakeholder Impact

• Shareholders are negatively impacted by the net loss and impairment charge, but may be encouraged by the adjusted EPS growth and U.S. Healthcare performance.
• Employees may be affected by the cost-saving initiatives and strategic portfolio review.
• Customers may see changes in the retail experience as the company focuses on engagement and value.
• Suppliers may be impacted by the company's strategic review and cost-saving measures.
• Creditors may be concerned about the negative free cash flow and overall financial performance.

Next Steps

• WBA will continue to focus on customer engagement and value.
• The company will strategically review its portfolio over the next three months.
• WBA will continue to execute its cost savings program to achieve $1 billion in savings this year.
• The company will hold a conference call to discuss the second quarter results on March 28, 2024.

Key Dates

Keywords

Walgreens Boots Alliance, WBA, Financial Results, Impairment Charge, Adjusted EPS, U.S. Healthcare, Retail Pharmacy, Pharmacy Sales, EBITDA, Cost Savings, VillageMD, Boots, Sales Growth